Vertaling van "ways in which this pathology " (Nederlands → Frans) :

Even though there now are classifications available that allow the clinical identification of different types of depression, it still remains a fact that it is difficult to recognise one in care practice, especially in primary health care, with there being numerous ways in which this pathology can present itself (masked depression, depression that manifests itself through diffuse and persistent somatic signs…).
S’il existe aujourd’hui des classifications permettant d’identifier les différents types de dépression sur le plan clinique, il n’en reste pas moins vrai qu’en pratique de soin et en particulier en première ligne, des repérages restent difficiles au vu des travestissements de cette pathologie (dépression masquée, dépression se manifestant par des signes somatiques diffus et persistants…).

In 2005 the way in which the CGG carried out this function when receiving, diagnosing and treating a person with depression was analysed.
En 2005, la manière dont les CGG remplissaient le rôle lors de l’accueil, du diagnostic et du traitement de la dépression a été analysée.

These experiences show that there are different ways in which post-hospital follow-up care can be provided to suicidal patients and that it is of crucial importance that there should be a system set in place that ensures that this is indeed the case.
Ces expériences nous montrent qu’il existe différentes manières d’assurer le suivi posthospitalier des suicidants.

Omnitrope, the pioneering biosimilar of the recombinant human growth hormone somatropin, has received regulatory approval as the first-ever biosimilar in Japan under the brand name Somatropin BS S.C. This approval paves the way for greater access to high-quality biopharmaceuticals in the world’s second-largest pharmaceuticals market and comes about three months after Japanese authorities published guidelines for a biosimilar regulatory pathway, which is based on similar scientific principles already in place in the European Union.
Omnitrope, biosimilaire pionnier de la somatropine, une hormone de croissance humaine recombinante, a obtenu une autorisation au Japon sous la marque Somatropin BS S.C. Il s’agit du premier biosimilaire à avoir été homologué dans ce pays.